Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Frost & Sullivan

May 12, 2021 – The biopharmaceutical industry is facing its biggest test in recent times. Biopharmaceutical companies must follow suit by adopting advanced manufacturing technologies, establishing public-private partnerships and placing sustainability at the core of the business strategy.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

Healthcare News Press Releases alliances biopharma biopharmaceutical Digital Health digital therapeutics Life Sciences medical device Medical Device Industry partner partnership pharma Pharmaceutical therapeutics

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

Healthcare News Press Releases Uncategorized alliances biopharma biopharmaceutical Digital Health digital therapeutics Life Sciences medical device Medical Device Industry partner partnership pharma Pharmaceutical therapeutics

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Healthcare News Press Releases artificial intelligence biopharmaceuticals biotechnology diagnostics Digital Health Pharmaceutical telehealth Virtual Care

Pfizer’s mix of science and grit alters the course of its COVID-19 response

McKinsey

Angela Hwang, Pfizer’s head of biopharmaceuticals, talks about breaking new ground when the pressure is on—and how having a deep company heritage can help. Insights on Life Sciences Pharmaceuticals Public health

First-time launchers in the pharmaceutical industry

McKinsey

Increasingly, small biopharmaceutical companies are launching their new drugs themselves rather than relying on large pharma companies to do it for them.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Healthcare News Press Releases Uncategorized artificial intelligence biopharmaceuticals biotechnology diagnostics Digital Health Pharmaceutical telehealth Virtual Care

Director/Account Supervisor

LaVoie Health Science Blog

Strong communications professional with account management skills needed for growing life science/biopharmaceutical practice. Join a growing health and science focused agency with exciting global innovator clients. Position requires solid experience in corporate communications planning and execution, earned media relations, content development, including messaging, corporate presentation updates and press release development.

Account Executive

LaVoie Health Science Blog

Strong detail oriented public relations/communications professional needed for growing life science/biopharmaceutical practice. Join a health science focused integrated communications agency and be part of the agency’s second phase of growth.

Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome

Frost & Sullivan

Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market.

LaVoieHealthScience Names James (Jim) Heins as Senior Vice President and Managing Director of its New York Practice

LaVoie Health Science Blog

In his new role, Heins will provide senior level communications counsel to LHS’s growing roster of biopharmaceutical, medical technology, health IT, and health care services clients. BOSTON & NEW YORK– NOVEMBER 12, 2020.

LifeOmic Applauded by Frost & Sullivan for Enabling More Cost-efficient, Targeted Holistic Precision Health with Its Interoperable Precision Health Solutions

Frost & Sullivan Manufacturing

It offers novel precision health and wellness software-as-a-service (SaaS) solutions to patients, healthcare providers (HCPs), employers, health plans, and biopharmaceuticals.

Global Water Scarcity and Hospitalization Rates Stimulate the Polymeric Membranes Market

Frost & Sullivan

Invest in Blood Transfusion and Apheresis Membranes to Accelerate Revenue Growth : The increasing demand for blood plasma to create plasma-derived biopharmaceutical products will drive the demand for apheresis and transfusion membranes.

Ecosystem Partnerships Extend and Evolve Alliances

Phoenix Consulting Group

Published by TIDWIT Inc. at June 2, 2020. An interview with Norma Watenpaugh, CEO & Founding Principal, Phoenix Consulting Group. Q: You have been involved with the channel and emerging ecosystems for some time. How has the concept of partnership evolved over the past several years?

Frost & Sullivan Hails Sphere Fluidics for Enabling Efficient, Faster, and More Cost-effective Single-cell Analysis with Its Microfluidic Platforms

Frost & Sullivan

The platform allows faster and more cost-effective development of new biopharmaceuticals.

Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for Its Unmatched Breadth of Services to Support Clinical Trials

Frost & Sullivan

Furthermore, LabCorp Drug Development draws on its deep expertise in antiviral drugs and vaccines, as well as partners with biopharmaceutical companies to develop treatment and vaccines for COVID-19 through improved detection methods.”